Therapeutic strategies that are proven effective in MTAP‐deleted cancers such as PRMT5 inhibitors and MTA‐cooperative PRMT5 inhibitors should be investigated in the context of low MTA AML. This evidence concerns the gene PRMT5 and acute myeloid leukemia.